Chelsea Therapeutics was a biopharmaceutical company specializing in the development of innovative products that addressed important unmet medical needs or offered alternatives to existing treatments. Chelsea's novel medication, Northera™ (droxidopa) for symptomatic neurogenic orthostatic hypotension was approved by the FDA in February 2014. The company was acquired by Lundbeck in June 2014.